Skip to main content
Device Global Header

Subscribe
or Renew

Advanced Search

This article is available to subscribers. Subscribe now. Already have an account? Sign in

Clinical Therapeutics

Belimumab for Systemic Lupus Erythematosus

List of authors.
  • Bevra Hannahs Hahn, M.D.

A 20-year-old woman with SLE presents with disease flares and receives belimumab, a monoclonal antibody that binds to B-cell activating factor, inhibiting B-cell stimulation. Belimumab is considered for patients who do not have a response or have adverse effects with first-line therapies.

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Dr. Hahn reports receiving consulting fees through her institution from UCB, Abbott Laboratories, and Eli Lilly; grant support through her institution from Aspreva Pharmaceuticals and Teva Pharmaceuticals; and fees for serving on a data and safety monitoring board from Anthera Pharmaceuticals. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the author are available with the full text of this article at NEJM.org.

Author Affiliations

From the Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles.

Address reprint requests to Dr. Hahn at the Department of Medicine, Division of Rheumatology, David Geffen School of Medicine at the University of California Los Angeles, 1000 Veteran Ave., Los Angeles, CA 90095, or at .

Print Subscriber? Activate your online access.